All In MedTech

FDA Clearance Tracker · P190002-S019

Saluda Medical Evoke® SCS System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 20, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 20, 2024

Approved

Time to decision

180 days

Received Sep 22, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P190002-S019
Device name
Saluda Medical Evoke® SCS System
Applicant location
Atarmon
Received
Sep 22, 2023
Decided
Mar 20, 2024
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P190002

Device type

Device class
Class III

Every decision under product code LGW

FDA's approval statement

As written in FDA's record.

Approval for expanding the indications to include diabetic peripheral neuropathy of the lower extremities

Source documents

Other decisions for Saluda Medical Pty, Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.